CMAJ • February 27, 2007; 176 (5). doi:10.1503/cmaj.060803.
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonovas, S.
Right arrow Articles by Sitaras, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonovas, S.
Right arrow Articles by Sitaras, N. M.
Related Collections
Right arrow Other oncology
Right arrow Drugs: cardiovascular system
Right arrow Adverse drug reactions
Right arrowRelated Articles

Does pravastatin promote cancer in elderly patients? A meta-analysis

Stefanos Bonovas and Nikolaos M. Sitaras

From the Department of Pharmacology (Bonovas, Sitaras), School of Medicine, University of Athens, and the Center for Disease Control and Prevention (Bonovas), Athens, Greece.


View this table:
[in this window]
[in a new window]

  		Table 1.

 

Figure 121
View larger version (28K):
[in this window]
[in a new window]

  		Fig. 1: Meta-analysis of pravastatin therapy and cancer risk. The risk ratios and 95% confidence intervals are displayed on a logarithmic scale. See abbreviations footnote in Table 1 for study name expansions.

 

Figure 221
View larger version (14K):
[in this window]
[in a new window]

  		Fig. 2: Risk ratios of cancer associated with pravastatin therapy as a function of the mean age of participants at enrolment. The greater the variance of a study, the smaller the area of the circle and the less that observation contributes to the overall effect. The superimposed line is obtained by random-effects meta-regression analysis using a restricted maximum likelihood method estimate of the residual heterogeneity variance. Risk ratios are displayed on a logarithmic scale. Regression equation: log risk ratio = –0.854 + 0.014 x age.

 

View this table:
[in this window]
[in a new window]

  		Table 2.